Historical review of thymosin α 1 in infectious diseases
- 22 June 2015
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Opinion on Biological Therapy
- Vol. 15 (sup1), 117-127
- https://doi.org/10.1517/14712598.2015.1033393
Abstract
Thymosin α 1 (Tα1) is a peptidic biological response modifier, which plays a significant role in activating and regulating various cells of the immune system. For the above-mentioned activities it is expected to exert a clinical benefit in the treatment of diseases where the immune system is altered. Several clinical trials have been carried out with Tα1 for treatment or prevention of many different infectious diseases such as hepatitis B and C, sepsis and Aspergillosis in bone marrow-transplanted patients. Data available on the use of Tα1 in infectious disease as well as a vaccine enhancer will be reviewed to possibly generate new working hypothesis. Tα1 has been widely used in thousands of patients. Nevertheless, there are some issues that have not yet been properly addressed (i.e., dose, schedule, combination treatments, end-points to be evaluated in clinical trials). In the most recent clinical trials Tα1 has been used at higher doses than those commonly used in the past showing a direct proportionality between the dose and the effect. The safety profile of Tα1 is excellent and it is virtually devoid of toxicity.This publication has 63 references indexed in Scilit:
- Large Randomized Study of Thymosin α 1, Interferon Alfa, or Both in Combination With Dacarbazine in Patients With Metastatic MelanomaJournal of Clinical Oncology, 2010
- Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysisVirology Journal, 2009
- Thymosin-α1 modulates dendritic cell differentiation and functional maturation from human peripheral blood CD14+ monocytesImmunology Letters, 2007
- The Pathophysiology and Treatment of SepsisThe New England Journal of Medicine, 2003
- Thymosin alpha one restores murine T-cell-mediated responses inhibited by In vivo cocaine administrationInternational Journal of Immunopharmacology, 1992
- Thymosin alpha 1 modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytesInternational Journal of Immunopharmacology, 1990
- Combination treatment using thymosin α1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in miceCancer Immunology, Immunotherapy, 1990
- Characterization of the immunoregulatory properties of thymosin alpha 1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytesInternational Journal of Immunopharmacology, 1989
- Effect of thymosin alpha one on specific antibody response and susceptibility to infection in young and aged miceInternational Journal of Immunopharmacology, 1985
- Hepatitis B Vaccine in Patients Receiving HemodialysisThe New England Journal of Medicine, 1984